Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
04 Oct 2022
04 Oct 2022
Historique:
received:
17
03
2022
revised:
30
06
2022
accepted:
12
08
2022
pubmed:
19
8
2022
medline:
6
10
2022
entrez:
18
8
2022
Statut:
ppublish
Résumé
Clinical guidelines have recommended patients with high-risk breast cancer to extend adjuvant hormone therapy beyond 5 years. However, the prevalence, predictors, and outcomes of extended adjuvant hormone therapy in the real world remain unknown. By linking six Swedish health registries, we prospectively followed 13,168 patients with breast cancer (2005-2020) from their first prescription of tamoxifen or aromatase inhibitors and categorized them as extending or not extending adjuvant hormone therapy. Cox regression analysis was used to investigate whether extended therapy was associated with breast cancer outcomes. Among patients with breast cancer who were recommended to extend adjuvant hormone therapy by the national guidelines, the proportion of women who extended therapy increased 5 folds during the past 10 years, reaching 80.9% during 2018 to 2020. Patients were more likely to extend therapy after completing 5-year adjuvant hormone therapy if they were young [40 vs. ≥65 years: OR, 1.71; 95% confidence interval (CI), 1.13-2.58], had positive lymph nodes (OR, 2.25; 95% CI, 1.85-2.73), had high tumor grade (grade 3 vs. 1: OR, 1.79; 95% CI, 1.34-2.39), received chemotherapy (OR, 5.22; 95% CI, 4.19-6.50), had first-degree relatives who died from breast cancer (OR, 1.84; 95% CI, 1.21-2.81), or had a high income (OR, 1.23; 95% CI, 1.01-1.49). Extended use of adjuvant hormone therapy was statistically significantly associated with improved disease-free survival (HR, 0.72; 95 CI%, 0.55-0.95). This study provides real-world evidence showing the use and improved breast cancer outcomes of extended adjuvant hormone therapy beyond 5 years. The proportion of patients with breast cancer extending adjuvant hormone therapy beyond 5 years has increased dramatically in recent years, which is associated with improved patient outcomes.
Identifiants
pubmed: 35980311
pii: 708038
doi: 10.1158/0008-5472.CAN-22-0900
pmc: PMC9530643
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Hormones
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3614-3621Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Breast Cancer Res. 2014 Aug 27;16(4):427
pubmed: 25436920
J Clin Oncol. 2008 Apr 20;26(12):1965-71
pubmed: 18332472
J Clin Oncol. 2015 Jul 10;33(20):2262-9
pubmed: 26033800
J Clin Oncol. 2012 Mar 1;30(7):718-21
pubmed: 22042967
J Clin Oncol. 2019 Feb 10;37(5):423-438
pubmed: 30452337
J Clin Oncol. 2016 Mar 20;34(9):927-35
pubmed: 26786933
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
J Clin Oncol. 2010 Aug 10;28(23):3784-96
pubmed: 20625130
Ann Oncol. 2014 Oct;25(10):1966-1972
pubmed: 25057175
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
BMC Public Health. 2019 May 2;19(1):495
pubmed: 31046737
Int J Cancer. 2012 May 1;130(9):2103-10
pubmed: 21630259
J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83
pubmed: 18695137
Ann Oncol. 2010 May;21 Suppl 5:v9-14
pubmed: 20555111
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Lancet Oncol. 2021 Oct;22(10):1458-1467
pubmed: 34543613
Lancet Oncol. 2017 Nov;18(11):1502-1511
pubmed: 29031778
Methods Mol Biol. 2011;675:215-20
pubmed: 20949391
J Surg Oncol. 2009 Sep 1;100(3):248-51
pubmed: 19330813
Lancet Oncol. 2019 Jan;20(1):88-99
pubmed: 30509771
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
N Engl J Med. 2003 Nov 6;349(19):1793-802
pubmed: 14551341
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
J Clin Oncol. 2011 Oct 20;29(30):4014-21
pubmed: 21911717
N Engl J Med. 2016 Jul 21;375(3):209-19
pubmed: 27264120
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Cancer Treat Rev. 2017 Nov;60:53-59
pubmed: 28881223
J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
pubmed: 16145047
Breast Cancer Res. 2007;9(3):R39
pubmed: 17598882
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53
pubmed: 18073378
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922781